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Summary
 
Inducible serum proteins whose concentrations oscillate between nontolerogenic and tolero-
genic levels pose a particular challenge to the maintenance of self-tolerance. Temporal restric-
tions of intrathymic antigen supply should prevent continuous central tolerization of T cells, in
analogy to the spatial limitation imposed by tissue-restricted antigen expression. Major acute-
phase proteins such as human C-reactive protein (hCRP) are typical examples for such induc-
ible self-antigens. The circulating concentration of hCRP, which is secreted by hepatocytes, is
induced up to 1,000-fold during an acute-phase reaction. We have analyzed tolerance to
hCRP expressed in transgenic mice under its autologous regulatory regions. Physiological reg-
ulation of basal levels (
 
,
 
10
 
2
 
9
 
 M) and inducibility (
 
.
 
500-fold) are preserved in female trans-
genics, whereas male transgenics constitutively display induced levels. Surprisingly, crossing of
hCRP transgenic mice to two lines of T cell receptor transgenic mice (specific for either a
dominant or a subdominant epitope) showed that tolerance is mediated by intrathymic deletion
of immature thymocytes, irrespective of widely differing serum levels. In the absence of induc-
tion, hCRP expressed by thymic medullary epithelial cells rather than liver-derived hCRP is
necessary and sufficient to induce tolerance. Importantly, medullary epithelial cells also express
two homologous mouse acute-phase proteins. These results support a physiological role of “ec-
topic” thymic expression in tolerance induction to acute-phase proteins and possibly other in-
ducible self-antigens and have implications for delineating the relative contributions of central
versus peripheral tolerance.
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olerance to self is a fundamental property of the im-
mune system. Several mechanisms, including physical
elimination (clonal deletion), receptor downregulation, and
functional inactivation (clonal anergy), acting both on im-
mature and mature T lymphocytes, have been shown to
contribute to tolerance induction in T cells. The individual
contribution of each single mechanism to the complex
phenomenon of T cell tolerance is difficult to assess. Nega-
tive selection of developing T cells apparently constitutes
the major mechanism of T cell tolerance. It is estimated
that about one half of all positively selectable T cells are re-
moved from the repertoire due to negative selection (1).
This process requires constant presentation of a given self-
antigen on MHC molecules of thymic APCs, and thus can
operate only for those antigens that either are expressed in-
trathymically (2) or are transported from the tissue of origin
into the thymus (3, 4). In addition to central tolerance, pe-
ripheral tolerance has been implicated in the case of “tis-
sue-restricted” self-antigens that are neither expressed nor
cross-presented in the thymus. A number of model systems
have been designed, in most cases with mice expressing an
MHC class I–restricted T cell receptor transgene and a tis-
sue-restricted neo–self-antigen, in which distinct mecha-
nisms of peripheral tolerance induction have been de-
scribed (5–8).
At face value, the prerequisites for tolerance induction to
MHC class II–restricted soluble proteins should be less
complex. Expression of MHC class II molecules is re-
stricted to professional APCs and thymic epithelium, and as
a rule presentation of epitopes on MHC class II requires in-
ternalization of a given antigen from the extracellular space.
For CD4 T cells, tolerance should be determined primarily
  
6
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by the concentration of the circulating protein rather than
the cell type of origin. Constitutively secreted self-antigens
equilibrate between the vascular and interstitial compart-
ments of lymphoid organs and will be presented by periph-
eral, as well as thymic, MHC class II–positive APCs (9).
Epitopes that are presented above a critical density within
the thymus will thus purge the developing T cell repertoire
of high avidity self-reactive T cells, whereas epitopes pre-
sented below a certain threshold will be ignored both in
the thymus and periphery, and thus T cells expressing such
TCRs should not pose a danger to self-tolerance (4, 8). An
additional safeguard in this delicate balance is provided by
the higher sensitivity of central tolerance induction in im-
mature thymocytes versus activation of mature T cells in
the periphery (10).
The above considerations apply to MHC class II–restricted
epitopes of proteins that are produced constitutively at con-
stant levels either in the thymus or the periphery. However,
in the case of inducibly secreted proteins with serum levels
that can vary over a wide range, blood-borne antigen may
not be sufficient to ensure tolerance imposition on the de-
veloping T cell repertoire. Under such circumstances, tem-
poral limitations of intrathymic antigen supply should pre-
vent continuous central tolerization of CD4 T cells, in
analogy to the spatial limitations imposed by tissue-restricted
antigen expression that prevent central tolerization of spe-
cific CD8 T cells. Acute-phase proteins (APPs)
 
1
 
 are a pro-
totypic example of such inducible self-antigens. APPs are a
class of liver-derived serum proteins with circulating con-
centrations that rapidly oscillate between trace amounts in
healthy individuals and up to 1,000-fold increased levels in
the course of induction under pathological conditions (11).
Several particular features would predict strong immu-
nogenicity of APPs upon induction:
 
 
 
(
 
a
 
) the presence of
very high serum levels (up to 2 mg/ml); (
 
b
 
) as part of the
innate immune response, APPs accumulate at the site of in-
fection and antigen processing; and (
 
c
 
) the uptake of APPs
by professional APCs may be facilitated by specific surface
receptors (12, 13). How is tolerance maintained under such
conditions? To address this issue, we have studied trans-
genic mice expressing human C-reactive protein (hCRP),
the major human APP, under control of all known autolo-
gous regulatory 
 
cis
 
-acting elements (14, 15). The physio-
logical regulation of hCRP is preserved in female trans-
genic mice, with basal levels of 
 
,
 
10
 
2
 
9 
 
M, which upon
experimental elicitation of an acute phase rise up to 500-
fold within a few hours (16). Due to hormonal influences,
basal levels in male hCRP transgenic mice are elevated (5 
 
3
 
10
 
2
 
7
 
 M, which incidentally equals the concentration in in-
duced females) and can be induced 20-fold (17). To date,
few data exist on the concentration range required for in-
 
duction of intrathymic deletion of CD4 T cells specific for
blood-borne antigens. CD4 T cells specific for the consti-
tutive serum component C5 are deleted at a physiological
concentration of 10
 
2
 
7
 
 M (4). Clonal deletion of thy-
mocytes specific for an immunoglobulin idiotype required
experimentally induced serum levels of 
 
.
 
10
 
2
 
6
 
 M (18). In
another model, Ig allotype–specific CD4 T cells were not
deleted at serum concentrations of 
 
z
 
10
 
2
 
8 
 
M (19). Extrapo-
lating from these observations, basal serum levels of hCRP
in female mice might thus lie below the threshold require-
ments for central tolerance (notwithstanding parameters
such as efficiency of antigen uptake, processing, and pre-
sentation, and TCR affinity). In contrast, hCRP levels ob-
served in female mice after induction may surpass this tol-
erance threshold and may even be sufficient to activate
peripheral T cells. We previously reported the intriguing
observation that female as well as male transgenic mice, de-
spite widely differing basal serum concentrations, are
equally tolerant to a dominant T cell epitope of hCRP, but
reactive to a subdominant epitope (16). In this study we
have addressed the mechanism of CD4 T cell tolerance at
the clonal level by crossing hCRP transgenic animals to
two strains of mice expressing transgenic TCRs specific for
either the dominant or the subdominant epitope of hCRP.
T cells of both specificities are deleted early in the thymus
of double transgenic animals. We show that ectopic expres-
sion of hCRP by medullary epithelial cells ensures central
tolerance irrespective of fluctuating serum levels.
 
Materials and Methods
 
Animals.
 
C57BL/6 and transgenic mice were kept under spe-
cific pathogen–free conditions in the animal facilities of the Ger-
man Cancer Research Center (Heidelberg, Germany). TCR and
hCRP transgenic mice were bred as heterozygotes.
 
Generation of TCR Transgenic Mice.
 
To generate TCR trans-
genic mice, rearranged V(D)J regions of TCRs from the hCRP-
specific T cell clones T1CRP6 and T3CRP2 were cloned into
the cassette vectors pT
 
a
 
cass and pT
 
b
 
cass (20; provided by D.
Mathis and C. Benoist, I.G.B.M.C., Strasbourg, France). Both
CD4 T cell clones were derived from a C57BL/6 mouse immu-
nized with hCRP. The TCR from clone T1CRP6 (dominant
epitope [
 
Dep
 
] TCR) recognizes the immunodominant epitope
(amino acid 89–101) of hCRP and the TCR from clone
T3CRP2 (subdominant [
 
Sep
 
] TCR) recognizes the subdominant
epitope (amino acid 80–94) of hCRP, both in the context of
MHC class II I-A
 
b 
 
(21).
The variable region of the 
 
Dep
 
 TCR contains rearranged
V
 
a
 
11.2/J
 
a
 
26 and V
 
b
 
5.1/D/J
 
b
 
1.6 elements. The rearranged re-
gions were amplified by PCR from genomic DNA of the T cell
clone T1CRP6 using the oligonucleotides 5
 
9
 
-GAG GAT CCC
GGG GAT TGG ACA GGG GCC-3
 
9
 
 (sense) and 5
 
9
 
-CAG
GCG GCC GCA TTG TTC AAA ATA C-3
 
9
 
 (antisense) for the
 
a
 
 chain, and 5
 
9
 
-ATC GAC TCG AGA GGA AGC ATG TCT
AAC-3
 
9
 
 (sense) and 5
 
9
 
-CCA AGA CCG CGG TCA TCC AAC
ACA G-3
 
9
 
 (antisense) for the 
 
b
 
 chain. Both PCR fragments were
digested with appropriate restriction enzymes (
 
a
 
 chain: PspAI/
NotI; 
 
b
 
 chain: XhoI/SstII) and cloned into pBluescript SK
 
1
 
(Stratagene, Heidelberg, Germany). After verification of the cor-
rect sequence, the fragments were subcloned into the cassette
 
1
 
Abbreviations used in this paper:
 
 APP, acute-phase protein; DC, dendritic
cell; 
 
Dep
 
, dominant epitope; DN, double negative; DP, double positive;
hCRP, human C-reactive protein; RIP, rat insulin promoter; mSAP,
mouse serum amyloid
 
 P 
 
component; 
 
Sep
 
, subdominant epitope; SP, sin-
gle positive; Tag, large T antigen. 
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vectors pT
 
a
 
cass and pT
 
b
 
cass resulting in constructs termed
pT
 
a
 
T1CRP6 and pT
 
b
 
T1CRP6.
The variable regions of the 
 
Sep
 
 TCR are encoded by V
 
a
 
4/
J
 
a
 
17 and V
 
b
 
8.3./D/J
 
b
 
1.6 elements. The following oligonucle-
otides were used to amplify these rearrangements: 5
 
9
 
-GAG GAC
CCG GGA ATA CCA CTC TGA AC-3
 
9
 
 (sense) and 5
 
9
 
-TCA
TCC GCG GCC GCC AAA ATA ACC CAC ACA C-3
 
9
 
 (anti-
sense) for the 
 
a
 
 chain, and 5
 
9
 
-GCA TAC TCG AGT CGC GAG
ATG GGC TCC-3
 
9
 
 (sense) and 5
 
9
 
-CCA AGA CCG CGG TCA
TCC AAC ACA G-3
 
9
 
 (antisense) for the 
 
b
 
 chain. The amplifica-
tion products were cloned into pSK
 
1
 
 and then into the respec-
tive TCR expression cassettes as described above, yielding the
vectors pT
 
a
 
T3CRP2 and pT
 
b
 
T3CRP2.
The constructs were functionally tested in vitro after elec-
troporation into the TCR-negative T cell hybridoma BW58 (see
reference 22). Recognition of the specific peptide–MHC com-
plex by the transfected TCR was assessed by IL-2 production
upon stimulation with BL/6 splenocytes and the respective pep-
tide.
Before microinjection, the pT
 
a
 
cass and the pT
 
b
 
cass vectors
were digested with SalI and KpnI, respectively, to remove
prokaryotic regions. The corresponding 
 
a 
 
and 
 
b
 
 chain constructs
were coinjected into (C57BL/6 
 
3 
 
C3H)F
 
2
 
 zygotes. Transgenic
founders were backcrossed to C57BL/6 for at least 5 generations.
The resulting mouse lines were termed 
 
Sep
 
 TCR-tg and 
 
Dep
 
TCR-tg according to expression of a TCR specific either for the
subdominant or dominant epitope of hCRP.
 
Thymus Organ Culture.
 
Fetal thymic lobes were removed
from embryos on day 14 of gestation (E14) and cultured on poly-
carbonate filters (Costar, Bodenheim, Germany) supported by
sponges (Upjohn, Erlangen, Germany) in 12-well plates contain-
ing 2 ml cell culture medium (Iscove’s medium, 10% FCS). Cul-
tures were kept in a humidified chamber at 37
 
8
 
C and 7% CO
 
2
 
 for
8 d before analysis.
 
Thymus Transplantation and Bone Marrow Reconstitution.
 
Fetal thy-
mic lobes (E15) were cultured in vitro (as described above) for
24 h to allow for genotyping of the donor embryos for the hCRP
transgene by slot blot. Two to four irradiated (5 Gy) lobes were
implanted under the kidney capsule of thymectomized host ani-
mals. 4 wk later, recipients were lethally irradiated (9.5 Gy) and
reconstituted with T cell–depleted 
 
Dep
 
-tg bone marrow (5 
 
3 
 
10
 
6
 
cells/animal). Immunization or phenotype analysis of grafted ani-
mals was carried out after another 6–8 wk.
 
Immunization and T Cell Proliferation Assays.
 
Immunizations were
performed as previously described (16). In brief, mice were im-
munized in the foot pads of the hind legs with 100 
 
m
 
g of peptide
emulsified in CFA (PBS/CFA vol/vol 1:1). 8–9 d later, popliteal
and inguinal lymph nodes were removed. Cells were cultured for
72 h in triplicates at 4 
 
3 
 
10
 
5
 
 cells/well in flat-bottomed 96-well
plates in serum-free medium (HL-1; Boehringer Ingelheim, In-
gelheim, Germany) in the presence or absence of peptide. Prolif-
eration was measured by incorporation of [
 
3
 
H]Tdr, which was
added for the last 12 h of culture (1 
 
m
 
Ci/well).
 
Flow Cytometric Analysis.
 
Lymphocytes were stained with
the following antibodies in various combinations according
to standard procedures: FITC-coupled anti-V
 
b
 
5.1 (MR9-4; Phar-
Mingen, San Diego, CA); RR8-1 (reference 23); FITC-coupled
anti-V
 
b
 
8.3 (1B3.3; PharMingen); FITC-coupled anti-pan TCR-
 
b
 
(H57-579; reference 24); Red-613– or biotin-coupled H129.19
(anti-CD4; Gibco-BRL, Eggenstein, Germany); and Red-613–
or PE-coupled anti-CD8 (53-6.7; Gibco-BRL). mAb anti-V
 
a
 
11
was detected with an anti–rat F(ab)
 
2
 
 fragment coupled to PE
(Tagoimmunologicals, Biosource, Fleuris, Belgium). Biotinylated
antibodies were detected using Red-670–coupled streptavidin
(Gibco-BRL) or Cy5 (Dianova, Hamburg, Germany). Three-
color fluorescence was analyzed on a FACScan
 
Ò
 
 (Becton Dickin-
son, Heidelberg, Germany) and four-color fluorescence on a
FACSvantage
 
Ò
 
 (Becton Dickinson). Data were collected from vi-
able lymphocytes by appropriate forward and side scatter gating.
Data analysis was performed with Cellquest software (Becton
Dickinson).
 
Enrichment of Thymic Stromal Cells.
 
Thymi of young adult
mice were finely minced and then slowly stirred in medium for 5
min at room temperature to release the bulk of free thymocytes.
The tissue fragments were subsequently slowly stirred in a colla-
genase/dispase mixture (25) for two rounds of 20 min at 37
 
8
 
C.
Tissue fragments remaining after the second round were vigor-
ously pipetted to further facilitate release of epithelial cells. Both
collagenase/dispase fractions were pooled, washed, and filtered
for further cell enrichment. The majority of thymocytes was re-
moved by depletion of CD4-positive cells using mAb GK1.5 (26)
and sheep anti–rat IgG magnetic beads (Dynal, Oslo, Norway).
Subsequently, Fc receptors were blocked by a brief incubation
with Ab 2.4G2. Isolation of stromal cells from this CD4-depleted
cell suspension was performed in two ways. Three successive
rounds of positive selection by magnetic beads (Miltenyi Biotec
GmbH, Bergisch Gladbach, Germany) were applied using a mod-
ification of a previously described protocol (27). First, macro-
phages and dendritic cells (DCs) were enriched using Abs F4/80
(28) and N418 (29); second, cortical epithelial cells were enriched
using Ab CDR1 (30); and third, medullary epithelial cells were
enriched using Ab G8.8 (31). Alternatively, CD4-depleted cells
were divided into three aliquots and each was subjected to a sin-
gle step of positive selection by magnetic beads using the same
surface markers. The second protocol routinely yielded higher
cell numbers. Hemopoietic cells were separately enriched before
complement lysis using an anti-CD45 Ab (T-200; reference 32).
All Abs except for anti-CD45 were biotinylated and streptavidin
beads or goat anti–rat beads were used as second step reagents.
MiniMACS separation columns (type MS) were used for positive
selection according to the manufacturer’s manual. The purity of
cortical and medullary epithelial cells was assessed by costaining of
cytospins for cytokeratin, using mAb Lu-5 (Boehringer Mannheim,
Mannheim, Germany) detected by anti–mouse IgG
 
1
 
-FITC (Di-
anova) and an independent marker for medullary epithelial cells
TR-5 (33), coupled to Cy3 (Amersham, Braunschweig, Ger-
many). In the G8.8-selected fraction, 
 
.
 
90% of keratin-positive
cells coexpressed TR-5.
Reverse Transcriptase PCR Analysis of Acute-phase Gene Expression.
RNA was isolated from tissues using TRIZOL (Gibco-BRL) fol-
lowed by DNase treatment to remove genomic DNA or from
single cell suspensions using the High Pure RNA Isolation Kit
(Boehringer Mannheim). 2 mg of total RNA were reversely tran-
scribed into cDNA using Superscript II Reverse Transcriptase
(Gibco-BRL). PCR analyses were performed using 1/10 of this
reaction. The following oligonucleotides were used: for hCRP:
hCRP 2 (sense) 59-CCA TGG AGA AGC TGT TGT G-39 (22
to 116), hCRP 3 (antisense) 59-CTG TGA CTT CAG GAA
CCT C-39 (306 to 324), and hCRP 1 (antisense) 59-CAA ATG
TGT ACT GGA GCT AC-39 (324 to 344); for mouse C-reac-
tive protein: mCRP 1 (sense) 59-CCA TGG AGA AGC TAC
TCT G-39 (22 to 117), mCRP 2 (antisense) 59-GTG TAG
CCC TTG TGC AG (418 to 434) and mCRP 3 (antisense) 59-
CCC AAG ATG ATG CTT GC-39 (448 to 464); for mouse se-
rum amyloid P component (mSAP): mSAP 1 (sense) 59-CAA
GCA TGG ACA AGC TG-39 (-5 to 12), mSAP 2 (antisense) 59-8 Self-tolerance to Inducible Acute-phase Proteins
CCC AAG TGG TAC ATA GG-39 (338 to 355), and mSAP 3
(antisense) 59-CAA CAA TGC CAG AGG AG-39 (360 to 376).
Figures given in brackets refer to the position of the primers rela-
tive to the translation start site. The positions of all sense and re-
spective antisense primers are located in different exons, so that
PCR products originating from contaminating genomic DNA
could be excluded. Efficiency of cDNA synthesis was controlled
using the b-actin–specific oligonucleotides 59-TGG AAT CCT
GTG GCA TCC ATG AAA C-39 (sense) and 59-TAA AACC
GCA GCT CAG TAA CAG TCC G-39 (antisense) under non-
saturating conditions (,24 cycles).
A first round of PCR was performed using the primer pairs
hCRP 1/2, mCRP 1/3, or mSAP 1/3. PCR conditions were
948C for 3 min, 30 cycles of 948C for 1 min, 548C for 1 min,
728C for 1 min, and a final elongation step of 728C for 5 min. For
nested reamplification of 1/20 of the PCR products, the primer
combinations hCRP 2/3, mCRP 1/2, or mSAP 1/2 were used.
The number of PCR cycles in the reamplification was adjusted to
a minimum to ensure nonsaturating conditions in order to allow
for semiquantitative estimates of RNA expression. All PCR reac-
tions were carried out in a volume of 50 ml, using 1 U of Taq
Polymerase (MBI Fermentas, Vilnius, Lithuania). Amplification
products (15 ml) were analyzed on 1.5% agarose gels.
Results
Transgenic Expression of a/b-TCRs Recognizing Two
Epitopes of hCRP: Development and Selection. CD4 T cells
of C57BL/6 mice respond against two epitopes of hCRP
when immunized with complete protein or peptides corre-
sponding to either epitope (16, 21). Transgenic mice ex-
pressing hCRP as a neo–self-antigen under control of its
autologous regulatory elements are tolerant to the immuno-
dominant and reactive to the subdominant epitope of
hCRP. Responsiveness to the subdominant epitope is only
revealed by peptide but not by protein immunization. This
differential tolerance is independent of basal serum levels
that can vary by three orders of magnitude. To address the
underlying tolerance mechanisms at the clonal level, we
generated two strains of TCR transgenic mice.
The transgenic line termed Dep expresses a TCR that is
specific for the dominant epitope of hCRP-spanning resi-
dues 89–101 and encodes a Va11 and a Vb5.1 region. Ex-
pression and selection of the Dep TCR during develop-
ment was followed by costaining for the transgenic Va and
Vb chains. Selection of double positive (DP) thymocytes
into the CD4 lineage in H-2b mice is highly efficient with
.90% of CD4 single positive (SP) thymocytes expressing
the Dep TCR and a ratio of CD4/CD8 SP thymocytes of
at least 8:1 (Fig. 1). Selection of the Dep TCR is lost in
mice expressing a reduced diversity of self-peptides, i.e., in-
variant chaino/o mice (34), EpAbIio/o transgenic mice (refer-
ence 35 and our unpublished data), and H-2Mao/o mice
(36). The surface density of the Dep TCR is fivefold in-
creased on DP thymocytes when compared with wild-type
levels, but does not exceed physiological levels on mature
SP thymocytes, as judged by expression of CD3e (data not
shown). The efficient positive selection is also reflected in
the periphery with a CD4/CD8 ratio of 10:1 and z85% of
peripheral CD4 T cells expressing both transgenic TCR
chains at high levels. These cells are activated in vivo upon
intravenous injection of peptide hCRP 89–101, as reflected
by their phenotype 24 h thereafter (CD691, HSAhi, CD62Llo;
data not shown).
The second TCR transgenic line, termed Sep, expresses
a TCR that is specific for the subdominant epitope of
hCRP-spanning residues 80–94 and encodes a Va4 and a
Vb8.3 region. Based on the analysis of the Vb8.3 epitope,
the Sep TCR shows a similar expression pattern as the Dep
TCR, i.e., early expression on double negative (DN) thy-
mocytes, a physiological density of CD3 complexes on SP
Figure 1. Positive and negative selection of CD4 thymocytes specific
for the dominant epitope of hCRP. Thymocytes of BL/6, TCR single
transgenic Dep, and Dep 3 hCRP female mice were stained for coexpres-
sion of CD4 and CD8 (a) and the transgenic TCR chains Va11 and
Vb5.1 (b), and were analyzed by four-color fluorescence. Note the effi-
cient positive selection of TCR transgenic CD4 T cells in single trans-
genic mice and their deletion at the DP stage in noninduced Dep 3
hCRP mice. The total number of thymocytes (mean 6 SD of at least
three animals) and the percentages of subsets per quadrant are indicated.
Male mice displayed an identical phenotype. Fluorescence intensity is
shown on a four-decade logarithmic scale. 6–10-wk-old mice were ana-
lyzed.9 Klein et al.
thymocytes, and a strong CD4 skewing among SP thy-
mocytes and peripheral T cells (Fig. 2). How is the devel-
opmental fate and immunocompetence of hCRP-specific
T cells influenced by various levels of this APP depending
on gender or induction status?
Early Negative Selection of hCRP-specific Thymocytes in
TCR  3  hCRP Mice: Tolerance Is Epitope-dependent, but Inde-
pendent of hCRP Serum Levels. Surprisingly, in both male
and female Dep 3 hCRP mice the size of the thymus was
at least 10-fold reduced despite widely differing basal serum
levels. This correlated with a relative and absolute reduc-
tion of DP and CD4 SP thymocytes. Among the remaining
DP and CD4 SP cells the frequency of Dep TCR-positive
cells was markedly reduced, and thymocytes expressing the
Dep TCR at high levels (TCRhi) were completely missing
(Fig. 1). T cells expressing the Dep TCR were rare in the
periphery (,3%; data not shown). This pattern was already
apparent in newborn mice (data not shown). Thus, dele-
tion of hCRP-reactive thymocytes specific for the domi-
nant epitope starts early during ontogeny and at an early
stage of their intrathymic development, namely the DP
stage. Likewise, several observations indicate that expres-
sion of the Sep TCR specific for the subdominant epitope
also results in intrathymic deletion. The thymus of Sep 3
hCRP double transgenic mice is reduced in size by 75%
and so is the absolute and relative number of CD4 SP thy-
mocytes when compared with Sep single transgenic mice
(Fig. 2). Moreover, peripheral Vb8.31 CD4 T cells express
endogenous TCR Va elements at higher frequencies (i.e.,
Va2 1 8 1 11, z18%) than do Sep single transgenic mice
(Va2 1 8 1 11, ,2%) indicating selection for Sep-negative or
Sep-low CD4 T cells (data not shown). Taken together,
the observed phenotypes of the TCR 3 hCRP strains in-
dicate that both T cell specificities are subject to intrathy-
mic deletion. How do these results comply with respon-
siveness to the subdominant epitope of the polyclonal
repertoire in hCRP single transgenic mice?
The observation that only 15% of the CD4 T cells
emerging in the Dep 3 hCRP mice express the transgenic
b chain suggests that coexpression of an endogenous a
chain in addition to the transgenic chains is not sufficient to
rescue  Dep-expressing cells from deletion. In contrast,
.70% of peripheral CD4 SP cells in the Sep 3 hCRP mice
still do express the transgenic b chain. Thus, negative selec-
tion of the transgenic TCR for the subdominant epitope
seems to be less stringent, allowing for exit of low affinity/
avidity T cells from the thymus. However, we cannot ex-
clude that subtle differences in the precise timing or level of
expression of these two transgenic TCRs influence the ob-
served differences in b chain allelic exclusion.
The notion of differential tolerance is supported by ob-
servations at the functional level. Immunization with pep-
tides corresponding to the antigenic epitope of each TCR
revealed that tolerance by intrathymic deletion is complete
only in Dep 3 hCRP mice, whereas Sep 3 hCRP mice,
despite deletion of the transgenic TCR, show a vigorous
proliferative response (Fig. 3). Again these differences were
sex independent within each transgenic line. Thus, T cell
tolerance to hCRP is dictated by epitope hierarchy rather
than circulating levels of antigen.
Central Tolerance Is Due to Ectopic Expression of hCRP in
the Thymus. Based on previous reports, the basal levels of
hCRP in male mice of z5 3 1027 M are compatible with
intrathymic deletion due to entry and presentation of
blood-borne antigen (4, 18). The at least 500-fold lower
levels in female mice (#1029 M) are more difficult to rec-
oncile with the observed phenotype of early and complete
intrathymic deletion. Moreover, pronounced deletion oc-
curred in fetal thymus organ cultures (FTOC) of Dep 3
hCRP thymi in the absence of blood-borne antigen supply
(data not shown). We thus considered an additional in-
trathymic source of hCRP leading to continuous and suffi-
cient presentation of hCRP epitopes in the thymic mi-
croenvironment irrespective of circulating levels. Two
major cell populations, hemopoietic and radio-resistant ep-
ithelial cells, were assessed as a putative source of ectopi-
cally expressed hCRP.
In view of previous reports on a membrane-bound form
of CRP being expressed by subsets of macrophages in hu-
man and rat (13, 37, 38), we first assessed the influence of
hCRP transgenic hemopoietic cells on the development of
Dep cells. When lethally irradiated B6 mice were reconsti-
tuted with bone marrow cells from Dep 3 hCRP mice,
thereby generating animals in which only hemopoietic cells
carried the hCRP transgene, no deletion of the Dep TCR
was observed. The central and peripheral compartments of
these mice were identical to those of B6 mice reconstituted
with Dep single transgenic bone marrow, i.e., mice lacking
Figure 2. Positive and negative selection of CD4 thymocytes specific
for the subdominant epitope of hCRP. Thymocytes of BL/6, TCR single
transgenic Sep, and Sep 3 hCRP female mice were stained for coexpres-
sion of the transgenic TCR chain Vb8.3, CD4, and CD8, and were ana-
lyzed by three-color fluorescence. CD4 versus CD8 expression (a) and
Vb8.3 expression gated on the CD4 SP subset (b) are shown. Note the
strong bias towards CD4 SP T cells in TCR single transgenic mice and its
reversion in noninduced Sep 3 hCRP mice. The total number of thy-
mocytes (mean 6 SD of at least three animals) and the percentages of sub-
sets per quadrant are indicated. Male mice displayed an identical pheno-
type. 6–10-wk-old mice were analyzed.10 Self-tolerance to Inducible Acute-phase Proteins
the hCRP transgene (Fig. 4). Bone marrow–derived cells
(macrophages, DCs, and T and B cells) thus do not provide
a source of thymic hCRP that would lead to deletion of
specific T cells. This conclusion is also supported by the
observation that hCRP mice reconstituted with Dep TCR
bone marrow, mice in which all cells except hemopoietic
cells carry the hCRP transgene, exhibit the same degree of
deletion as Dep 3 hCRP mice (Fig. 4).
To assess the role of thymic epithelial cells in tolerance
to hCRP, we constructed chimeric animals in which only
radioresistant thymic stromal cells, i.e., epithelial cells, carry
the hCRP transgene. Thymectomized B6 mice were
grafted with an irradiated (5 Gy) hCRP transgenic thymus
and reconstituted with Dep TCR bone marrow. In these
animals, early and profound deletion of the Dep TCR was
observed (Fig. 5 a) indicating that thymic epithelial cells do
produce hCRP and that this source is sufficient to induce
negative selection of specific T cells in the absence of liver-
derived antigen. We next asked whether epithelium-derived
hCRP is also necessary for negative selection. Endogenous
hCRP transgenic thymus in male and female hCRP trans-
genic mice was replaced by fetal B6 thymi and, after recon-
stitution with Dep bone marrow cells, the differentiation of
Dep TCR T cells was followed. In male hCRP transgenic
mice deletion was seen within the B6 thymus graft (Fig. 5
a). Interestingly, the onset and extent of this deletion was
indistinguishable from that observed in double transgenic
mice or in a B6 animal grafted with an hCRP transgenic
thymus (see Figs. 1 and 4). Thymus-derived antigen and
high levels of blood-borne antigen thus cause the same
phenotype of intrathymic deletion. In contrast, in female
hCRP mice carrying a B6 thymus, no intragraft deletion
was observed (Fig. 5 a). The cellular composition of these
grafts was identical to B6 grafts carried by nontransgenic re-
cipients. Immunization of these chimeras resulted in a
strong proliferative response of peripheral Dep T cells (Fig.
5 b) and simultaneous central deletion of Dep thymocytes
(data not shown). The latter is most likely caused by in-
creased serum levels of hCRP due to concomitant induc-
tion of an acute phase.
In summary, these data show that ectopic expression of
hCRP by thymic epithelial cells is (a) sufficient to cause de-
letion of a T cell repertoire largely consisting of hCRP-
specific cells and (b) necessary to ensure tolerance at low
basal hCRP serum levels in female mice, which correspond
to the levels found in healthy humans.
Transgenic hCRP Mimics Expression of Endogenous Murine
APPs and of hCRP in Humans. The thymus transplanta-
tion experiments did not formally rule out the possibility of
antigen carry-over by intrathymic APCs. Liver-derived an-
tigen might have been taken up by MHC class II–positive
cells from the circulation of the fetal donor and presented
at tolerogenic levels during the experimental period of z10
wk. Given the turnover of peptide–MHC complexes on
thymic APCs (39), and the turnover of thymic DCs (40),
this explanation is unlikely. To directly demonstrate the in-
trathymic origin of hCRP, the expression pattern of hCRP
was analyzed by reverse transcriptase PCR. As expected,
hCRP mRNA was readily detectable in the liver of hCRP
transgenic male mice (Fig. 6 a). A weaker signal was repro-
ducibly obtained with RNA extracts from the thymus of
these mice. Under the same conditions all other organs
tested (spleen, brain, heart, kidney, and lung) did not yield
a signal. Further amplification of the PCR products with
nested primers revealed additional signals in brain, kidney,
and lung (data not shown). The signal in liver and thy-
mus of noninduced female hCRP transgenic animals was
weaker and sometimes undetectable, but upon induction of
an acute-phase response, the hCRP-specific signals strongly
increased in liver and thymus (data not shown).
Since ectopic expression of transgenes is often attributed
to positional effects, we asked whether intrathymic expres-
Figure 3. Epitope-specific T
cell tolerance in hCRP and
hCRP  3  TCR transgenic mice.
(a) BL/6, hCRP single trans-
genic, and Dep 3 hCRP male
and female mice were immu-
nized with a peptide correspond-
ing to the dominant epitope of
hCRP. (b) BL/6, hCRP single
transgenic, and Sep 3 hCRP fe-
male mice were immunized with
a peptide corresponding to the
subdominant epitope of hCRP.
8–10 d later, draining lymph
node cells were assessed for their
proliferative response to the re-
spective peptide. Irrespective of
gender, hCRP single and Dep 3
hCRP mice are tolerant to the
dominant epitope, whereas
hCRP single and Sep 3 hCRP
mice respond to the subdomi-
nant epitope.11 Klein et al.
sion of the hCRP transgene mimics the tissue-specificity of
endogenous APPs. The expression analysis was extended to
two endogenous murine APPs with homology to hCRP,
namely mouse CRP (mCRP) and mSAP. Messenger RNA
of mCRP could be detected by reverse transcriptase PCR
in liver and thymus of male and female mice irrespective of
experimental induction of an acute phase (Fig. 6 a). This
constitutive expression is in accordance with CRP being a
minor APP in mice, which is only weakly induced during
the course of an acute-phase response. Similarly, expression
of mSAP, the major murine APP, was detectable in the
liver and thymus of noninduced male and female animals
(Fig. 6 a). Upon induction, these signals increased in
strength in the liver, as expected for a major APP, and also
in the thymus (data not shown). Analysis of various human
tissues also revealed ectopic expression of hCRP in the
postnatal human thymus (age 3 mo; Fig. 6 b). Thus, the or-
gan-specific expression and the induction pattern of the
hCRP transgene closely resemble those of its functional
murine homologue mSAP and of hCRP in humans.
Prenatal Onset of Ectopic Expression. Since central dele-
tion of Dep TCR transgenic thymocytes already occurred
during the fetal period (data not shown), intrathymic ex-
pression of hCRP during ontogeny was assessed. In accor-
dance with the prenatal onset of tolerance induction,
hCRP mRNA was detectable by reverse transcriptase PCR
in fetal thymi of E15 embryos (earliest time point tested;
Fig. 6 c). Likewise, mSAP and mCRP were expressed in
thymi without any gender difference (data not shown).
Thus, both murine APP and the human transgene are ex-
pressed in the thymus throughout the pre- and early post-
natal period, when the bulk of the T cell repertoire is gen-
erated.
Medullary Epithelial Cells Express APPs. As shown above,
an hCRP source in radioresistant thymic stromal cells
rather than in bone marrow–derived cells was responsible
for deletion of Dep T cells in the absence of liver-derived
hCRP (Figs. 4 and 5). To delineate this cell type more pre-
cisely, we enriched hemopoietic cells (mostly thymocytes),
monocytes (macrophages and DCs), cortical epithelial cells,
or medullary epithelial cells using appropriate cell surface
markers. These cell subsets were enriched either sequen-
tially or separately (see Materials and Methods). Since the
marker used for medullary epithelial cells (G8.8) is also
weakly expressed on cortical epithelial cells (31), it was im-
portant to deplete cortical epithelial cells before selection of
G8.8-positive cells. Irrespective of the enrichment proce-
dure, reverse transcriptase PCR analyses on cDNA pre-
pared from these thymic cell fractions revealed expression
of transgenic hCRP as well as endogenous mCRP and
mSAP exclusively in medullary epithelial cells (Fig. 6 d).
Discussion
The surprising finding of early and profound central de-
letion of T cells specific for both epitopes of hCRP even at
very low levels of circulating protein, and the striking simi-
larity of intrathymic T cell fate and peripheral reactivity ir-
respective of 500-fold differing serum levels prompted us
to reanalyze the tissue specificity of hCRP expression.
Figure 4. Thymic deletion is not due to hemopoietic cell–derived
hCRP. BL/6 and hCRP transgenic mice were lethally irradiated and re-
constituted either with bone marrow cells from Dep or Dep 3 hCRP do-
nors. 8 wk later, intrathymic selection of Dep T cells was analyzed by
four-color fluorescence (see Fig. 1). Coexpression of the transgenic TCR
chains Va11 and Vb5.1 on CD4 SP thymocytes is shown. Deletion is in-
dependent of the presence of the hCRP transgene in the donor bone
marrow.
Figure 5. Thymus-derived
hCRP is necessary and sufficient
for tolerance in female hCRP
transgenic mice. Thymecto-
mized male and female hCRP
transgenic mice were grafted
with fetal BL/6 thymi, and
thymectomized female BL/6
mice were grafted with hCRP
transgenic thymi. 4 wk later, ani-
mals were lethally irradiated and
reconstituted with Dep trans-
genic bone marrow. After an-
other 6 wk intrathymic selection
of Dep T cells was analyzed by
four-color fluorescence (see Fig.
1). Coexpression of the trans-
genic TCR chains Va11 and Vb5.1 on CD4 SP thymocytes is shown (a).
The same type of animals were immunized with peptide hCRP 89–100
(see Fig. 3) to assess their tolerance status (b). Thymus-derived hCRP is
necessary in female, but not in male, hCRP transgenic mice for central
deletion of hCRP-specific T cells and tolerance.12 Self-tolerance to Inducible Acute-phase Proteins
Transplantation experiments as well as reverse transcriptase
PCR analyses revealed expression of hCRP in medullary
epithelial cells of the thymus. We consider this “ectopic”
expression of the neo–self-antigen to be physiological for
several reasons. (a) The hCRP transgene spans a region of
31 kb containing all known autologous 59 and 39 cis-acting
elements (15). Liver-specificity (as formerly assessed by
northern blotting) and inducibility of hepatic gene expres-
sion indicate that the trans-acting factors are conserved in
mouse and humans (14). (b) We show that ectopic expres-
sion of hCRP is exclusively restricted to medullary epithe-
lial cells of the thymus. Gene-regulation in this cellular
subset of the thymus is comparable to that in hepatocytes
with regard to onset during ontogeny, and, surprisingly, in-
ducibility and sexual dimorphism. (c) Importantly, we dem-
onstrate that hCRP is also expressed in the human thymus
and that the homologous APPs of the mouse (mSAP and
mCRP) show a cell type–specific expression pattern, iden-
tical to the hCRP transgene. It is noteworthy that hCRP
and mSAP, two species-specific major APPs, are inducible
in medullary cells of the thymus (data not shown), indicat-
ing the presence of all components of the signaling cascade
(cytokine receptors, second messengers, and transcription
factors) that hitherto were thought to be confined to hepa-
tocytes and a macrophage subset (38).
Several neo–self-antigens under direction of putatively
tissue-specific promoters have been found to be expressed
in the thymus of transgenic mice. These include the pro-
moters of rat insulin II (41, 42), rat elastase I (43), guinea
pig a-lactalbumin, human beta globin (44, 45), keratin-IV
(46), and metallothionein (47). Thymic expression of dif-
ferent model antigens driven by these heterologous regula-
tory elements was often variable and usually found in some
but not all transgenic lines, consistent with the notion that
the integration site and/or the copy number influence ex-
pression. In this context it is noteworthy that a truncated
version of the hCRP promoter directing expression of an
MHC class I alloantigen was active in hepatocytes but not
in the thymus (as assessed by selection of specific T cells in
chimeras and PCR analysis; reference 48). In view of the
variability and unpredictability of the thymic activity of
these hybrid transgenes, it was initially difficult to assess the
biological significance of this ectopic gene expression.
However, recent studies revealed a diverse group of en-
dogenous “peripheral” antigens to be expressed in the thy-
mus of rodents or primates, including pancreas-specific
genes (41), components of the myelin sheath (myelin basic
protein and myelin proteolipid protein; references 49–51),
S-100b (52), acetylcholine receptor (53), retinal proteins
(arrestin and interphotoreceptor retinoid–binding protein;
reference 54), and neuro-endocrine hormones (55). Thus,
thymic expression of “tissue-specific” genes seems to be a
common occurrence and to be part of physiological ex-
pression patterns. This should result in a more diverse pre-
sentation of “self” within the thymus than has been ap-
preciated previously. Although a role of intrathymic
Figure 6. Expression pattern of transgenic hCRP and endogenous murine APPs. (a) The organ-specific expression pattern of the hCRP transgene and
the homologous mouse APPs (mCRP and mSAP) was analyzed by reverse transcriptase PCR (35 cycles) in a young adult, noninduced, male hCRP
transgenic mouse. Expression of the hCRP transgene parallels that of endogenous APPs and is confined to liver and thymus. An identical pattern was
identified for induced female hCRP animals under the same PCR conditions. Signals for hCRP and mSAP, but not of mCRP, in liver and thymus of
noninduced females were consistently lower (detection of thymic expression required reamplification with nested primers). The weak mCRP band in the
kidney was not consistently detected. Ht, heart; Br, brain; Sp, spleen; Th, thymus; Lu, lung; Ki, kidney; Li, liver; Co, control. (b) The organ-specific ex-
pression pattern of hCRP was analyzed in various human tissues. Expression is confined to liver and thymus. St, stomach; Sk, skin; Ms, muscle. (c) Ex-
pression of hCRP in thymus and liver was analyzed during ontogeny in noninduced hCRP transgenic females. Expression in both organs was detected
from day E15 onwards to adulthood. Thymus samples were reamplified with nested primers. (d) Expression of hCRP, mCRP, and mSAP was analyzed
in whole thymocytes and in highly enriched thymic subsets of a noninduced female hCRP mouse (reverse transcriptase PCR; 30 cycles). Expression of
the hCRP transgene and endogenous APP is confined to medullary epithelial cells. Note that detection of APP expression in enriched medullary epithe-
lial cells of noninduced female mice does not require nested reamplification.13 Klein et al.
expression of “nonthymic” proteins in the establishment of
self-tolerance has been proposed, it has not been formally
demonstrated. Nevertheless, intriguing correlations be-
tween the thymic expression level of self-antigens and the
propensity to spontaneously develop or succumb to experi-
mental induction of autoimmune disease have been re-
cently reported for insulin (56, 57) and two retinal proteins
(54). Our analysis demonstrates for the first time that thy-
mic expression of a secreted neo–self-antigen under its au-
tologous regulatory elements confers tolerance upon the
developing T cell repertoire by deletion of specific T cells
with remarkable efficiency.
Expression of several “peripheral” antigens has been as-
signed to the thymic medulla by histological analysis (50,
52, 58), although delineation of the precise cell type has
been difficult. Expression of hCRP and mouse APP is
clearly confined to radio-resistant stromal cells as shown by
transplantation experiments, and more precisely to medul-
lary epithelial cells as shown by cell separation and subse-
quent reverse transcriptase PCR. Medullary epithelial cells
have been previously implicated in tolerance induction
both by deletion or anergy induction (46, 59–61). How
does the restriction of hCRP expression to the medulla
comply with the profound deletion phenotype, in particu-
lar the lack of immature DP thymocytes, most of which re-
side in the cortex? We suggest that hCRP is secreted by
medullary epithelial cells and subsequently presented by
MHC class II–positive APCs, including DCs and medul-
lary and cortical epithelial cells. Such intercellular antigen
transfer and “cross presentation” within the thymic mi-
croenvironment has been described for an MHC class II–
restricted membrane protein (62). Recognition of specific
peptide–MHC complexes on cortical epithelial cells would
result in deletion of hCRP-specific cells at the transition
from the DN to DP stage as soon as they become suscepti-
ble to apoptotic signals via the TCR (63; note that DN
thymocytes prematurely express the transgenic TCR at
high levels [Fig. 1]). Interestingly, an identical phenotype
of early intrathymic deletion is observed when hCRP is
derived either exclusively from epithelial cells (as in hCRP
grafts in B6 mice; Fig. 5 a) or from the circulation (as in B6
grafts in male hCRP transgenic mice; Fig. 5 a), arguing for
efficient antigen presentation on cortical cells in both in-
stances. In the latter case, hCRP may gain access to the
cortex via blood vessels or the capsule (64). Indeed, cortical
epithelial cells have been shown to be accessible to blood-
borne proteins (9) and to mediate deletion of immature
thymocytes in vitro and in fetal thymus organ cultures (25,
27). In support of this notion, hCRP protein can be di-
rectly visualized within the cortical parenchyma by immu-
nohistology in hCRP transgenic mice after experimental
induction (data not shown).
The proposed intrathymic “antigen spread” may explain
why deletion of hCRP-specific thymocytes is remarkably
efficient when compared with other experimental models
in which ectopic expression of heterologous transgene-
constructs was observed. Ectopic expression in the thymus
of various model-antigens under control of the rat insulin
promoter (RIP), for instance, yielded divergent results. No
central deletion of TCR transgenic CD4 cells specific for
the large T antigen (Tag) of SV 40 was observed in RIP-
Tag 3 TCR mice (22), yet tolerance of CD4 and CD8 T
cells could be demonstrated at the polyclonal level in RIP-
Tag single transgenic mice (58). Ectopic expression of the
nuclear protein of LCMV or the allo-MHC antigen Kb
driven by the RIP lead to partial tolerance among CD8 T
cells (42, 65). In the latter study, deletion of only those Kb-
specific T cells that express a transgenic TCR at high density
was described. Deletion of CD8 T cells was also incom-
plete when ectopic Kb expression was directed by the pro-
moters of guinea pig a-lactalbumin or human beta globin
(45). Intrathymic expression of Tag under the rat elastase I
promoter or MHC class I-Kb under the keratin IV pro-
moter resulted in anergy induction of specific CD8 T cells
rather than deletion (43, 46). Several reasons may account
for these different outcomes, namely antigen availability
(secreted versus intracellular antigens), the type of APC
(bone marrow–derived versus epithelial cell), and the affin-
ity/avidity of the TCR–MHC interaction (66, 67). Given
this variability, it will be important to test the contribution
of the thymic activity of each of these promoters to toler-
ance induction in their native genetic context.
Tolerance to a major murine APP has recently been
documented (68). Is ectopic expression of APPs necessary
for tolerance induction? Serum levels of hCRP in female
transgenic animals closely mimic hCRP levels in humans.
These basal levels of circulating hCRP are insufficient to
induce intragraft deletion and tolerance in transgenic fe-
male mice grafted with a B6 thymus. Upon induction of an
acute phase, hCRP levels in females rise 500-fold, and are
now sufficient to activate peripheral T cells (naive Dep and
Sep T cells, when transferred into hCRP transgenic animals
expand vigorously in male, but not in female recipients;
our unpublished results). Tolerance induction in the ab-
sence of a thymic antigen source would thus be confined to
irregular intervals of acute phases and likely to be insuffi-
cient to impose tolerance on a continuously developing T
cell repertoire. In contrast, expression of APPs in the pre-
and postnatal thymus results in presentation of both domi-
nant and subdominant epitopes at levels sufficient to confer
functional tolerance irrespective of an acute phase. Ectopic
expression by thymic medullary epithelial cells thus seems
to be a physiological device to safeguard tolerance to APPs.
Sensitive detection methods reveal the expression of a
growing number of “peripheral” antigens in the thymus,
yet based on the available number of MHC molecules on
thymic APCs, the number of self-peptides presented at
tolerogenic levels has to be limited. It will be important to
identify common biological and possibly genetic features
that have led to ectopic expression of certain “peripheral”
proteins during evolution.14 Self-tolerance to Inducible Acute-phase Proteins
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